Factory 99% Bicalutamide Powder CAS 90357-06-5 Chemical Intermediate Bicalutamide

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A472
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Bicalutamide
• CAS: 90357-06-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 10g
• Function: Anti-Cancer
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Bicalutamide
Appearance	White Powder
CAS NO.	90357-06-5
Molecular Formula	C26H20FN3O2
Storage	Keep in a cool, dry, dark location

 

Bicalutamide is a non-steroidal anti-androgen medication used in the treatment of prostate cancer. It belongs to a class of drugs known as androgen receptor inhibitors, which work by blocking the action of androgens (male hormones) in the body.

 

1. Prostate Cancer Treatment: Bicalutamide is primarily used in combination with other therapies, such as a luteinizing hormone-releasing hormone (LHRH) agonist or surgical removal of the testicles, for the treatment of prostate cancer.
2. Adjuvant Therapy: It may be used as adjuvant (additional) therapy to reduce the risk of disease recurrence after surgery or radiation therapy for prostate cancer.
3. Palliative Care: In some cases, bicalutamide may be used for palliative care to relieve symptoms and improve the quality of life for patients with advanced prostate cancer.

1. Androgen Receptor Blockade: Bicalutamide functions by competitively binding to androgen receptors in the body, thereby preventing the binding and activation of androgens.
2. Tumor Growth Inhibition: By blocking androgen receptor signaling, bicalutamide inhibits the growth and proliferation of prostate cancer cells that depend on androgens for their survival and growth.
3. Symptom Relief: In palliative care, it can help relieve symptoms such as pain, urinary problems, and bone fractures caused by advanced prostate cancer.